Patel, S
10/029871

FILE 'REGISTRY' ENTERED AT 14:52:55 ON 14 MAY 2002
L1 STR



VAR G1=CH/N
VAR G2=CH/N
VAR G3=CH/N
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE
L2 1544 SEA FILE=REGISTRY SSS FUL L1
L5 STR



VAR G1=CH/N
VAR G2=CH/N
VAR G3=CH/N
VAR G4=C/N/O/S
VAR G5=C/N/S
REP G6=(0-6) CH2
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE
L6 82 SEA FILE=REGISTRY SUB=L2 SSS FUL L5

100.0% PROCESSED 954 ITERATIONS 82 ANSWERS

Searcher : Shears 308-4994

SEARCH TIME: 00.00.03

FILE 'CAPLUS' ENTERED AT 14:56:05 ON 14 MAY 2002
L7 5 S L6 OR L6/D

E1 THROUGH E78 ASSIGNED

L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:31464 CAPLUS
DOCUMENT NUMBER: 134:100762
TITLE: Preparation of pyridine derivatives and medicinal use thereof
INVENTOR(S): Iino, Yukio; Fujita, Kohichi; Kodaira, Ariko; Hatanaka, Toshihiro; Takehana, Kenji; Kobayashi, Tsuyoshi; Konishi, Atsushi; Yamamoto, Takashi
PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan
SOURCE: PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001002359	A1	20010111	WO 2000-JP4298	20000629
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1193255	A1	20020403	EP 2000-940879	20000629
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.: JP 1999-187959 A 19990701
JP 2000-71706 A 20000315
WO 2000-JP4298 W 20000629

OTHER SOURCE(S): MARPAT 134:100762
GI



AB Heterocyclic compds. represented by the following general formula R1-CO-N(R2)-A-X-B-N(R3)-Y-(CH2)n-R4 [R1 = (un)substituted or cycloalkenyl; R2, R3 = H, alkyl; R4 = (un)substituted alkyl,

alkenyl, cycloalkyl, cycloalkenyl, aryl, or heterocyclyl having .gtoreq.1 heteroatom(s); A = (un)substituted heterocyclic ring; B = (un)substituted arom. or heterocyclic ring; n = 0-6; Y = a bond between atoms, CO, CO2, CONR5, C(S)NR5, SO, SO2 (wherein R5 = H, alkyl); X = a bond between atoms, O, OCHR7, CHR8O, O2C, CO2, OC(S), C(S)O, S, SO, SO2, SCHR9, CHR10S, SC(O), C(O)S, SC(S), C(S)S, SO2 NR11, NR12SO2, NR13, etc.; R7 - R10 = H, alkyl; R11 - R13 = H, alkyl, acyl] or pharmacol. acceptable salts thereof are prepd. These compds. have inhibitory effects on AP-1 activity, NF-kappa B activity, inflammatory cytokine prodn., matrix metalloprotease prodn., expression of inflammatory cell adhesion factor, etc. and are usable as drugs such as antiinflammatory, antirheumatic, antiviral agents, immunosuppressants, cancer metastasis inhibitors, and antiarteriosclerotics. Thus, 2-mercapto-5-nitropyridine was treated with NaH in DMF and then alkylated by 1-bromomethyl-4-nitrobenzene at room temp. for 1.5 h to give 2-(4-nitrobenzylthio)-5-nitropyridine which was reduced by Zn/AcOH in THF at room temp. for 16 h to 2-(4-aminobenzylthio)-5-aminopyridine and then acylated by 2,2-dimethylcyclopropanecarbonyl chloride in the presence of Et3N in CH2Cl2 at room temp. for 17 h to give 2-(4-(2,2-dimethylcyclopropanecarbonylamino)benzylthio)-5-(2,2-dimethylcyclopropanecarbonylamino)pyridine (I). I in vitro inhibited NF-kappa B activity with IC50 of 0.015 .mu.g/mL in an assay measuring .beta.-galactosidase activity expressed in HUVEC cells and driven by NF-kappa B-binding sequence-fused SV40 T antigen min. promoter.

IT **318967-19-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of pyridine derivs. as inhibitors of AP-1 activity, NF-kappa B activity, inflammatory cytokine prodn., matrix metalloprotease prodn., expression of inflammatory cell adhesion factor)

IT **318967-14-5P 318967-15-6P 318967-16-7P**
318967-17-8P 318967-18-9P 318967-20-3P
318967-21-4P 318967-22-5P 318967-23-6P
318967-28-1P 318967-30-5P 318967-31-6P
318967-34-9P 318967-35-0P 318967-36-1P
318967-37-2P 318967-38-3P 318967-39-4P
318967-40-7P 318967-44-1P 318967-45-2P
318967-46-3P 318967-47-4P 318967-48-5P
318967-49-6P 318967-50-9P 318967-51-0P
318967-52-1P 318967-55-4P 318967-56-5P
318967-57-6P 318967-58-7P 318967-59-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyridine derivs. as inhibitors of AP-1 activity, NF-kappa B activity, inflammatory cytokine prodn., matrix metalloprotease prodn., expression of inflammatory cell adhesion factor)

IT **318967-60-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of pyridine derivs. as inhibitors of AP-1 activity,

NF-kappa B activity, inflammatory cytokine prodn., matrix metalloprotease prodn., expression of inflammatory cell adhesion factor)

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:666734 CAPLUS
DOCUMENT NUMBER: 133:252451
TITLE: Preparation of biarylmethylaminopurines as potent cyclin/CDK inhibitors and antiproliferative agents.
INVENTOR(S): Trova, Michael P.
PATENT ASSIGNEE(S): Albany Molecular Research, Inc., USA
SOURCE: PCT Int. Appl., 174 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000055161	A1	20000921	WO 2000-US7065	20000316
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1165561	A1	20020102	EP 2000-918057	20000316
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.: US 1999-124829P P 19990317
US 2000-493790 A 20000128
WO 2000-US7065 W 20000316

OTHER SOURCE(S): MARPAT 133:252451
GI



AB Title compds. [I; R1, R4 = H, alkyl; X = N, CH; R2 = (substituted) Ph, naphthyl, pyridyl, pyrimidyl, thienyl, furyl, pyrrolyl, quinolinyl, isoquinolinyl, etc.; R3 = H, alkyl, alkenyl, (substituted) Ph, phenylalkyl, etc.; R3R4 = atoms to form a 5-8 membered ring; Y = H, OR1, NHR1, NHCOR3, NHSO2R3, etc.; Q = (CH2)n; n = 0-3; with provisos], were prepd. Thus, title compd. (II) (prepn. from 2,6-dichloropurine given) inhibited growth of BT-579, MCF7, and numerous other transformed cell lines with GI50 <0.01 .mu.M.

IT **294648-31-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of biarylmethylaminopurines as potent cyclin/CDK inhibitors and antiproliferative agents)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:191054 CAPLUS
DOCUMENT NUMBER: 132:222342
TITLE: Benzene derivatives and medicinal use thereof
INVENTOR(S): Iino, Yukio; Fujita, Kohichi; Tsuji, Takashi; Kodaira, Ariko; Takehana, Kenji; Kobayashi, Tsuyoshi; Yamamoto, Takashi
PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000015603	A1	20000323	WO 1999-JP4986	19990913
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9956502	A1	20000403	AU 1999-56502	19990913
BR 9913562	A	20010522	BR 1999-13562	19990913
EP 1113000	A1	20010704	EP 1999-943309	19990913
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
NO 2001001157	A	20010425	NO 2001-1157	20010307
US 2001018441	A1	20010830	US 2001-803107	20010312

PRIORITY APPLN. INFO.: JP 1998-257804 A 19980911
WO 1999-JP4986 W 19990913

OTHER SOURCE(S): MARPAT 132:222342

GI







AB Title compds. [I; X = CO, S, NH, O, SO2, CH2, CH2CH2, CHOH, CHOCH3, C:CH2, CHCH2OH, S:O, OCH2, SCH2, CH:CH, SO2NH, SO2NCH3, CONH, CONCH3; R = H, CH3, Cl; R1 = NHCOQ, 4-CH3OC6H4CH2CONH, 4-CH3OC6H4CH2CH2CH2NH, 4-CH3OC6H4CH2CH2CONH, NH2, 4(CH3)2NC6H4CH2CONH, 4-ClC6H4CH2CONH, NHCOCH3; R3 = Cl, CH3; Q = N-contg.-heterocyclo], stereoisomers, and pharmaceutically acceptable salts thereof are prepd. as AP-1 activation inhibitors, NF-kappa B activation inhibitors, inflammatory cytokine prodn. inhibitors, matrix metalloprotease prodn. inhibitors, inflammatory cell adhesion factor expression inhibitors, anti-inflammatory agents, antirheumatic agents, immunosuppressive agents, cancerous metastasis inhibitors, and remedies for arteriosclerosis or antiviral agents contg. the above compds. as the active ingredient. The title compd. II was prepd. and tested.

IT **261001-10-9P 261001-11-0P 261001-16-5P 261001-17-6P 261001-19-8P 261001-22-3P 261001-23-4P 261001-24-5P 261001-25-6P 261001-27-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of benzene derivs. as medicine)

IT **261001-12-1P 261001-13-2P 261001-14-3P 261001-18-7P 261001-20-1P 261001-21-2P 261001-26-7P 261001-28-9P 261001-31-4P 261001-32-5P 261001-33-6P 261001-34-7P 261001-35-8P 261001-36-9P 261001-42-7P 261001-43-8P 261001-46-1P 261001-51-8P 261001-52-9P 261001-53-0P 261001-63-2P 261164-66-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of benzene derivs. as medicine)

IT **261001-37-0P 261001-39-2P 261001-40-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of benzene derivs. as medicine)

IT **261001-29-0P 261001-41-6P 261001-45-0P 261001-61-0P 261001-62-1P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of benzene derivs. as medicine)

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:763862 CAPLUS
DOCUMENT NUMBER: 132:442
TITLE: Aryl compounds, and preparation thereof, having IgE-affecting properties
INVENTOR(S): Sircar, Jagadish; Richards, Mark L.; Campbell, Michael G.; Major, Michael W.
PATENT ASSIGNEE(S): Avanir Pharmaceuticals, USA

SOURCE: PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9961013	A2	19991202	WO 1999-US11363	19990521
WO 9961013	A3	20000406		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ, DE, DE, DK, DK, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9941978	A1	19990521	AU 1999-41978	19990521
EP 1077695	A2	20010228	EP 1999-925756	19990521
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9910640	A	20011030	BR 1999-10640	19990521
NO 2000005887	A	20010119	NO 2000-5887	20001121

PRIORITY APPLN. INFO.: US 1998-86494P P 19980522
WO 1999-US11363 W 19990521

OTHER SOURCE(S): MARPAT 132:442

AB Small mol. inhibitors of the IgE response to allergens are provided which are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic.

IT **251340-11-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(aryl compd. prepn. for inhibition of IgE response)

L7 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1969:491119 CAPLUS
DOCUMENT NUMBER: 71:91119
TITLE: Pesticidal cyclopropanecarboxanilides
INVENTOR(S): Janiak, Stefan
PATENT ASSIGNEE(S): CIBA Ltd.
SOURCE: Ger., Offen., 32 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1803084		19690619		

PRIORITY APPLN. INFO.: CH 19671019

GI For diagram(s), see printed CA Issue.

AB I were active against insect pests, acarina, nematodes, phytopathogenic fungi and bacteria, and gastropodes. Chemosterilant activity was observed in houseflies particularly from cyclopropanecarbox-2-nitranilide and the 4-iodoanilide. Rat toxicity was LD50 .gtoreq.6 g./kg. body wt. I were prepd. by treating the appropriate aniline with cyclopropanecarboxylic acid, its acid halide, anhydride, or ester or by subsequent halogenation or alkylation of the anilide. To a cooled, stirred mixt. of 39 g. of 2,4,5,-Cl3-C6H2NH2, 16 ml. pyridine, and 500 ml. EtOAc was slowly added 20.9 g. cyclopropanecarbonyl chloride in 50 ml. EtOAc to give 52 g. I (R = H, R1 = 2,4,5-Cl3), m.165.7.degree. (benzene). I (R = H) similarly prepd. were (R1 and m.p. given): 4-MeO-2-NO2, 118-21.degree.; 2-Cl-5-CF3, 104-6.degree.; 2,5-Cl2, 145-6.degree.; 4-Cl-2-Me, 181-2.degree.; 3,5-(CF3)2, 162-3.degree.; 5-Cl-2-MeO, 94-7.degree.; 4-Cl-2-MeO-6-Me, 142-6.degree.; 2,4-Me2, 157-60.degree.; 3,4,5-Cl3, 163-5.degree.; 2,4-Cl2-6-O2N, 115-18.degree.; 4-Br-2-Me, 185-7.degree.; 2-Br-4-Me, 130-2.degree.; 3-Cl-2-Me, 165-6.degree.; 5-Cl-2-Me, 154-5.degree.; 2-Cl-4-NO2, 163-5.degree.; 4-Cl-2-NO2, 107-9.degree.; 2-MeO-4-NO2, 149-51.degree.; 2-MeO-5-NO2, 186-8.degree.; 2-MeO-5-Me-4-NO2, 155-7.degree.; 4-Cl-2,5-(MeO)2, 126-8.degree.; 3,5-Cl2, 162-4.degree.; 2-Br-5-CF3, 93-5.degree.; 4-Me, 159-61.degree.; 2-Me-4-NO2, 200-3.degree.; 4-H2N-3,5-Cl2, 208-11.degree.; 2,4-Br2-5-CF3, 153-5.degree.; 3-Cl-4-Me2N, 112-13.degree.; 4-Cl-2-EtO2C, -; 4-Br, 183-5.degree.; 3-Me, 95-7.degree.; 4-I, 209-11.degree.; 3-Br, 139-41.degree.; 3-Cl, 140-2.degree.; 4-NCS-3-Me, 128-30.degree.; 3-Cl-4-NCS, 97-100.degree.; 3-Cl-4-MeO, 124-5.degree.; 4-Me2N, 170-1.degree.; 4-MeS, 132-5.degree.; 2-Cl-4-MeS, -; 2,6-Cl2-4-MeS, -; 4-HO2C, 273-9.degree.; 4,5-Cl2-2-O2N, 131-4.degree.; 4-NCS, 116-18.degree.; 4-cyano, 202-4.degree.; 3,5-Br2-4-HO, 163-5.degree.; 4-MeO, 128-30.degree.; 4-Ac, 176-8.degree.; 4-H2NSO2, 263-6.degree.; 4-H2NSO2-2-HO, 228-9.degree.; 4-MeSO2, -; H, 101-3.degree.; 4-MeNHSO2, -; 4-I-3-Me, 146-8.degree.; 4-F, 160-1.degree.; 3-Cl-4-Me, 140-3.degree.; 3-Cl-4-I, 147-9.degree.; 3,4-Cl2, 126-8.degree.; 3-CF3, 118-20.degree.; 2-Cl-6-Me, 145-7.degree.; 3,4-Me2, 134-6.degree.; 4-Cl-3-CF3, 117-19.degree.; 4-Br-3-Cl, 125-6.degree.; 4-Br-2-CF3, 165-6.degree.; 3-I, 121-3.degree.; 5-Et2NSO2-2-Me, 164-6.degree.; 4-NO2, 175-7.degree.; 4-Cl-3-Me, 249-50.degree.; 2-Cl, 108-10.degree.; 2-NO2, 117-19.degree.; 3-Cl-4-CF3, 128-9.degree.; 2,6-Et2, 167-8.degree.; 4-cyclopropanecarboxamido (A), >250.degree.; 3-MeS, 106-9.degree.; 4-MeO-3-NO2, 134-7.degree.; 4-CF3, 171-3.degree.; 5-H2NSO2-2-HO, 228-9.degree.; 4-A-2,6-Cl2, 265-6.degree.; 4-HO, 205-7.degree.; 3-Br-4-Cl, 114-15.degree.; 2,4-Br2 167-9.degree.; 4-(4-methoxyphenoxy) 163-5.degree.; 4-Br-2-Cl, 157-9.degree.; 4-cyclopropanecarbonyloxy-3,5-dibromo, 195-8.degree.; 4-[4-(cyclopropanecarboxamido)benzyl] 247-8.degree.; 4-carbamoyl, >260.degree.; 4-(2-pyrrolidinon-1-yl), 219-20.degree.; 3-chloro-4-(2-chlorophenoxy), 160-2.degree., 4-(2,5-dichlorophenoxy), 159-61.degree.; 4-(4-chloro-2-methylphenoxy), 156-8.degree.; 3-chloro-4-(2,4-dichloro-6-methylphenoxy), 183-5.degree.; 4-Cl, 165-7.degree.; and 2,4-dichloro, 157-60.degree.. Also similarly prepd. I were: R1 = 4-MeO, R = Me, b0.cntdot.04 100-5.degree., and I, R1 = H, R = Ph, m. 42-6.degree.. I were formulated in the usual manner; pesticidal (including ovicidal) data were given. In the table above, NCS stands for thiocyanato.

IT **23737-36-2P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

[redacted] ENTERED AT 14:57:08 ON 14 MAY 2002
L8 78 SEA FILE=REGISTRY ABB=ON PLU=ON (23737-36-2/BI OR
251340-11-1/BI OR 261001-10-9/BI OR 261001-11-0/BI OR
261001-12-1/BI OR 261001-13-2/BI OR 261001-14-3/BI OR
261001-16-5/BI OR 261001-17-6/BI OR 261001-18-7/BI OR
261001-19-8/BI OR 261001-20-1/BI OR 261001-21-2/BI OR
261001-22-3/BI OR 261001-23-4/BI OR 261001-24-5/BI OR
261001-25-6/BI OR 261001-26-7/BI OR 261001-27-8/BI OR
261001-28-9/BI OR 261001-29-0/BI OR 261001-31-4/BI OR
261001-32-5/BI OR 261001-33-6/BI OR 261001-34-7/BI OR
261001-35-8/BI OR 261001-36-9/BI OR 261001-37-0/BI OR
261001-39-2/BI OR 261001-40-5/BI OR 261001-41-6/BI OR
261001-42-7/BI OR 261001-43-8/BI OR 261001-45-0/BI OR
261001-46-1/BI OR 261001-51-8/BI OR 261001-52-9/BI OR
261001-53-0/BI OR 261001-61-0/BI OR 261001-62-1/BI OR
261001-63-2/BI OR 261164-66-3/BI OR 294648-31-0/BI OR
318967-14-5/BI OR 318967-15-6/BI OR 318967-16-7/BI OR
318967-17-8/BI OR 318967-18-9/BI OR 318967-19-0/BI OR
318967-20-3/BI OR 318967-21-4/BI OR 318967-22-5/BI OR
318967-23-6/BI OR 318967-28-1/BI OR 318967-30-5/BI OR
318967-31-6/BI OR 318967-34-9/BI OR 318967-35-0/BI OR
318967-36-1/BI OR 318967-37-2/BI OR 318967-38-3/BI OR
318967-39-4/BI OR 318967-40-7/BI OR 318967-44-1/BI OR
318967-45-2/BI OR 318967-46-3/BI OR 318967-47-4/BI OR
318967-48-5/BI OR 318967-49-6/BI OR 318967-50-9/BI OR
318967-51-0/BI OR 318967-52-1/BI OR 318967-55-4/BI OR
318967-56-5/BI OR 318967-57-6/BI OR 318967-58-7/BI OR
318967-59-8/BI OR 318967-60-1/BI)

Random RN≤1 Strs display ↓

=> d 1,15,28,36-38,47,58,62,77,78 ide can

L8 ANSWER 1 OF 78 REGISTRY COPYRIGHT 2002 ACS
RN **318967-60-1** REGISTRY
CN Cyclopropanecarboxamide, N-[6-[4-[[(2,2-dimethylcyclopropyl)carbonyl]amino]benzoyl]-3-pyridinyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H27 N3 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

Searcher : Shears 308-4994

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:100762

L8 ANSWER 15 OF 78 REGISTRY COPYRIGHT 2002 ACS
RN **318967-44-1** REGISTRY
CN Benzamide, N-[4-[[5-[[(2,2-dimethylcyclopropyl)carbonyl]amino]-2-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H23 N3 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:100762

L8 ANSWER 28 OF 78 REGISTRY COPYRIGHT 2002 ACS
RN **318967-21-4** REGISTRY
CN Cyclopropanecarboxamide, N-[6-[4-[[(2,2-dimethylcyclopropyl)carbonyl]amino]phenoxy]-3-pyridazinyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C22 H26 N4 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:100762

L8 ANSWER 36 OF 78 REGISTRY COPYRIGHT 2002 ACS
RN **294648-31-0** REGISTRY
CN Cyclopropanecarboxamide, N-[trans-4-[[6-[[(4-bromophenyl)methyl]amino]-9-(1-methylethyl)-9H-purin-2-yl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C25 H32 Br N7 O
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:252451

L8 ANSWER 37 OF 78 REGISTRY COPYRIGHT 2002 ACS
RN **261164-66-3** REGISTRY
CN Cyclopropanecarboxamide, N-[3-[[4-[[(2,2-dimethylcyclopropyl)carbonyl]amino]phenyl]methyl]phenyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H30 N2 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:222342

L8 ANSWER 38 OF 78 REGISTRY COPYRIGHT 2002 ACS
RN **261001-63-2** REGISTRY
CN Benzenebutanamide, N-[4-[[4-[[(2,2-dimethylcyclopropyl)carbonyl]amino]phenyl]methyl]phenyl]-4-methoxy- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C30 H34 N2 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:222342

L8 ANSWER 47 OF 78 REGISTRY COPYRIGHT 2002 ACS
RN **261001-42-7** REGISTRY
CN Cyclopropanecarboxamide, N,N'-[(hydroxymethylene)di-4,1-phenylene]bis[2,2-dimethyl-, (1R,1'S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C25 H30 N2 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



Me Me

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:222342

L8 ANSWER 58 OF 78 REGISTRY COPYRIGHT 2002 ACS
RN **261001-29-0** REGISTRY
CN Cyclopropanecarboxamide, N,N'-(sulfinyldi-4,1-phenylene)bis[2,2-dimethyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H28 N2 O3 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



Me Me

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:222342

L8 ANSWER 62 OF 78 REGISTRY COPYRIGHT 2002 ACS
RN **261001-25-6** REGISTRY
CN Cyclopropanecarboxamide, N,N'-[(2-azidoethylidene)di-4,1-phenylene]bis[2,2-dimethyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C26 H31 N5 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:222342

L8 ANSWER 77 OF 78 REGISTRY COPYRIGHT 2002 ACS
RN **251340-11-1** REGISTRY
CN Cyclopropanecarboxamide, N,N'-(methylenedi-4,1-phenylene)bis[2,2-dimethyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H30 N2 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:442

L8 ANSWER 78 OF 78 REGISTRY COPYRIGHT 2002 ACS
RN **23737-36-2** REGISTRY
CN Cyclopropanecarboxanilide, 4',4'''-methylenebis- (8CI) (CA INDEX NAME)
FS 3D CONCORD
MF C21 H22 N2 O2
LC STN Files: BEILSTEIN*, CA, CAPLUS, CHEMCATS, TOXCENTER
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 71:91119

[redacted] ENTERED AT 14:59:03 ON 14 MAY 2002
L9 0 S L8

[redacted] ENTERED AT 14:59:12 ON 14 MAY 2002
L10 3 S L8

L10 ANSWER 1 OF 3 USPATFULL
ACCESSION NUMBER: 2002:17463 USPATFULL
TITLE: Compounds having IgE affecting properties
INVENTOR(S): Sircar, Jagadish C., San Diego, CA, UNITED STATES
Richards, Mark L., La Jolla, CA, UNITED STATES
Campbell, Michael G., Durham, NC, UNITED STATES
Major, Michael W., Glendale, WI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002010343	A1	20020124
APPLICATION INFO.:	US 2001-882340	A1	20010614 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1999-316870, filed on 21 May 1999, GRANTED, Pat. No. US 6271390

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-86494P	19980522 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KNOBBE MARTENS OLSON & BEAR LLP, 620 NEWPORT CENTER DRIVE, SIXTEENTH FLOOR, NEWPORT BEACH, CA, 92660
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
LINE COUNT: 1089
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to small molecule inhibitors of the IgE response to allergens which are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 2 OF 3 USPATFULL
ACCESSION NUMBER: 2001:145304 USPATFULL
TITLE: Benzene derivatives and Pharmaceutical use thereof
INVENTOR(S): Iino, Yukio, Kawasaki-Shi, Japan
Fujita, Kohichi, Kawasaki-Shi, Japan
Tsuji, Takashi, Kawasaki-Shi, Japan
Kodaira, Ariko, Kawasaki-Shi, Japan
Takehana, Kenji, Kawasaki-Shi, Japan
Kobayashi, Tsuyoshi, Kawasaki-Shi, Japan
Yamamoto, Takashi, Kawasaki-Shi, Japan
PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Chuo-ku, Japan (non-U.S.

corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001018441	A1	20010830
APPLICATION INFO.:	US 2001-803107	A1	20010312 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 1999-JP4986, filed on 11 Sep 1999, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1998-257804	19980911

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: OBLON SPIVAK MCCLELLAND MAIER & NEUSTADT PC, FOURTH FLOOR, 1755 JEFFERSON DAVIS HIGHWAY, ARLINGTON, VA, 22202
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
LINE COUNT: 1362
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides an AP-1 activation inhibitor, NF-kappa B activation inhibitor, inflammatory cytokine production inhibitor, matrix metalloprotease production inhibitor, inflammatory cell adhesion molecule expression inhibitor, anti-inflammatory agent, antirheumatic agent, immunosuppressant, cancer metastasis inhibitor, remedy for arteriosclerosis and antiviral agent which contain the benzene derivative of the following general formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 3 OF 3 USPATFULL
ACCESSION NUMBER: 2001:126151 USPATFULL
TITLE: Suppression of the IgE-dependent allergic response by benzimidazole analogs
INVENTOR(S): Sircar, Jagadish C., San Diego, CA, United States
Richards, Mark L., La Jolla, CA, United States
Campbell, Michael G., Durham, NC, United States
Major, Michael W., Glendale, WI, United States
PATENT ASSIGNEE(S): Avanir Pharmaceuticals, San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6271390	B1	20010807
APPLICATION INFO.:	US 1999-316870		19990521 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-86494P	19980522 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Higel, Floyd D.
LEGAL REPRESENTATIVE: Knobbe, Martens, Olson & Bear LLP
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1

Searcher : Shears 308-4994

LINE COUNT: 962
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to small molecule inhibitors of the IgE response to allergens which are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

FILE 'MARPAT' ENTERED AT 14:59:33 ON 14 MAY 2002
L5 STR



VAR G1=CH/N
VAR G2=CH/N
VAR G3=CH/N
VAR G4=C/N/O/S
VAR G5=C/N/S
REP G6=(0-6) CH2
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE

ATTRIBUTES SPECIFIED AT SEARCH-TIME:
MLEVEL IS CLASS ON RING NODES AND RING GROUPS
MLEVEL IS CLASS ON CHAIN NODES AND CHAIN GROUPS
ECLEVEL IS LIM ON ALL NODES
ALL RING(S) ARE ISOLATED

L12 212 SEA FILE=MARPAT SSS FUL L5 (MODIFIED ATTRIBUTES)
L13 STR



VAR G1=CH/N
VAR G2=CH/N
VAR G3=CH/N
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 14
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS E3 C AT 17

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 22

STEREO ATTRIBUTES: NONE

ATTRIBUTES SPECIFIED AT SEARCH-TIME:
MLEVEL IS CLASS ON RING NODES AND RING GROUPS
MLEVEL IS CLASS ON CHAIN NODES AND CHAIN GROUPS
ECLEVEL IS LIM ON ALL NODES
ALL RING(S) ARE ISOLATED

L14 [redacted] SUB=L12 SSS FUL L13 (MODIFIED ATTRIBUTES)

100.0% PROCESSED 211 ITERATIONS [redacted] 4 ANSWERS
SEARCH TIME: 00.00.20

L14 ANSWER 1 OF 4 MARPAT COPYRIGHT 2002 ACS
ACCESSION NUMBER: 134:207722 MARPAT
TITLE: Preparation of aromatic and heterocyclic compounds having cyclopropanecarboxamide moieties as inhibitors of NF-kappa B activation, inflammatory cytokine production, matrix metalloprotease production and inflammatory cell adhesion factor expression
INVENTOR(S): Iino, Yukio; Fujita, Kohichi; Yamamoto, Takashi; Takehana, Kenji; Kobayashi, Tsuyoshi
PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001016091	A1	20010308	WO 2000-JP5914	20000831

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: JP 1999-247483 19990901

GI



I

AB The title compds. I [R1 to R4 represent each Me, etc.; R5 and R6 represent each hydrogen, alkyl, etc.; A = (un)substituted arylene, etc.] are prepd. I are useful as antiinflammatory agents, antirheumatic agents, immunosuppressants, cancer metastasis inhibitors, antiviral agents. Compds. of this invention in vitro showed IC50 values of 1 .mu.g/mL to 4 .mu.g/mL against NF-kappa B activity.

IC ICM C07C233-60
ICS C07C233-62; C07C317-22; C07D213-75; A61K031-167; A61K031-44; A61P029-00; A61P031-12; A61P035-04; A61P037-06; A61P043-00

CC 27-16 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1, 24, 25

ST arom heterocycle nuclear factor kappa B inhibitor; antiinflammatory immunosuppressant antiviral metastasis inhibitor arom heterocycle

IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(NF-kappa B; prepn. of arom. and heterocyclic compds. having cyclopropanecarboxamide moieties as inhibitors of NF-kappa B activation or inflammatory cytokine prodn.)

IT Antitumor agents
(arom. and heterocyclic compds. having cyclopropanecarboxamide moieties with activity against NF-kappa B activation or inflammatory cytokine prodn., matrix metalloprotease prodn.)

IT Cell adhesion
(factor, inflammatory; prepn. of arom. and heterocyclic compds. having cyclopropanecarboxamide moieties as inhibitors of NF-kappa B activation or inflammatory cytokine prodn.)

IT Neoplasm
(metastasis; prepn. and effect of arom. and heterocyclic compds. having cyclopropanecarboxamide moieties with activity against NF-kappa B activation or inflammatory cytokine prodn.)

IT Anti-inflammatory agents
Antirheumatic agents
Antiviral agents
Immunosuppressants
(prepn. of arom. and heterocyclic compds. having cyclopropanecarboxamide moieties as inhibitors of NF-kappa B activation or inflammatory cytokine prodn.)

IT Cytokines
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(prepn. of arom. and heterocyclic compds. having cyclopropanecarboxamide moieties as inhibitors of NF-kappa B activation or inflammatory cytokine prodn.)

IT 329011-28-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of arom. and heterocyclic compds. having cyclopropanecarboxamide moieties as inhibitors of NF-kappa B activation or inflammatory cytokine prodn.)

IT 329011-29-2P 329011-31-6P 329011-33-8P 329011-35-0P
329011-37-2P 329011-39-4P 329011-41-8P 329011-43-0P
329011-45-2P 329011-47-4P 329011-49-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of arom. and heterocyclic compds. having cyclopropanecarboxamide moieties as inhibitors of NF-kappa B activation or inflammatory cytokine prodn.)

IT 141907-41-7, Matrix metalloprotease
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(prepn. of arom. and heterocyclic compds. having cyclopropanecarboxamide moieties as inhibitors of NF-kappa B activation or inflammatory cytokine prodn.)

IT 136-17-4, 2,4-Diaminodiphenylamine 141-86-6, 2,6-Diaminopyridine 2479-46-1, 1,3-Bis(4-aminophenoxy)benzene 2687-27-6 2716-10-1 3491-12-1, 1,4-Bis(4-aminophenoxy)benzene 5840-10-8 13080-85-8, 4,4'-Bis(4-aminophenoxy)biphenyl 13080-86-9, 2,2-Bis[4-(4-aminophenoxy)phenyl]propane 13080-89-2, Bis[4-(4-aminophenoxy)phenyl]sulfone 39070-63-8, 3,4-Diaminobenzophenone 50675-57-5, 2,2-Dimethylcyclopropanecarbonyl chloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of arom. and heterocyclic compds. having cyclopropanecarboxamide moieties as inhibitors of NF-kappa B activation or inflammatory cytokine prodn.)

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 2 OF 4 MARPAT COPYRIGHT 2002 ACS
ACCESSION NUMBER: 134:100762 MARPAT

TITLE: Preparation of pyridine derivatives and medicinal use thereof
INVENTOR(S): Iino, Yukio; Fujita, Kohichi; Kodaira, Ariko; Hatanaka, Toshihiro; Takehana, Kenji; Kobayashi, Tsuyoshi; Konishi, Atsushi; Yamamoto, Takashi
PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan
SOURCE: PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001002359	A1	20010111	WO 2000-JP4298	20000629
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1193255	A1	20020403	EP 2000-940879	20000629
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.: JP 1999-187959 19990701
JP 2000-71706 20000315
WO 2000-JP4298 20000629

GI



AB Heterocyclic compds. represented by the following general formula R1-CO-N(R2)-A-X-B-N(R3)-Y-(CH2)n-R4 [R1 = (un)substituted or cycloalkenyl; R2, R3 = H, alkyl; R4 = (un)substituted alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl, or heterocyclyl having .gtoreq.1 heteroatom(s); A = (un)substituted heterocyclic ring; B = (un)substituted arom. or heterocyclic ring; n = 0-6; Y = a bond between atoms, CO, CO2, CONR5, C(S)NR5, SO, SO2 (wherein R5 = H, alkyl); X = a bond between atoms, O, OCHR7, CHR8O, O2C, CO2, OC(S), C(S)O, S, SO, SO2, SCHR9, CHR10S, SC(O), C(O)S, SC(S), C(S)S, SO2 NR11, NR12SO2, NR13, etc.; R7 - R10 = H, alkyl; R11 - R13 = H, alkyl, acyl] or pharmacol. acceptable salts thereof are prepd. These compds. have inhibitory effects on AP-1 activity, NF-kappa B activity, inflammatory cytokine prodn., matrix metalloprotease prodn., expression of inflammatory cell adhesion factor, etc. and

are usable as drugs such as antiinflammatory, antirheumatic, antiviral agents, immunosuppressants, cancer metastasis inhibitors, and antiarteriosclerotics. Thus, 2-mercapto-5-nitropyridine was treated with NaH in DMF and then alkylated by 1-bromomethyl-4-nitrobenzene at room temp. for 1.5 h to give 2-(4-nitrobenzylthio)-5-nitropyridine which was reduced by Zn/AcOH in THF at room temp. for 16 h to 2-(4-aminobenzylthio)-5-aminopyridine and then acylated by 2,2-dimethylcyclopropanecarbonyl chloride in the presence of Et3N in CH2Cl2 at room temp. for 17 h to give 2-(4-(2,2-dimethylcyclopropanecarbonylamino)benzylthio)-5-(2,2-dimethylcyclopropanecarbonylamino)pyridine (I). I in vitro inhibited NF-kappa B activity with IC50 of 0.015 .mu.g/mL in an assay measuring .beta.-galactosidase activity expressed in HUVEC cells and driven by NF-kappa B-binding sequence-fused SV40 T antigen min. promoter.

IC C07D211-58; C07D213-75; C07D213-76; C07D237-20; C07D237-22; C07D239-42; C07D239-48; C07D277-44; A61K031-44; A61K031-445; A61K031-50; A61K031-505; A61P029-00

CC 27-16 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1

ST pyridine prepn antiinflammatory; antirheumatic pyridine prepn; antiviral immunosuppressant pyridine prepn; cancer metastasis inhibitor pyridine prepn; antiarteriosclerotics pyridine prepn

IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)
(AP-1 (activator protein 1); prepn. of pyridine derivs. as inhibitors of AP-1 activity, NF-kappa B activity, inflammatory cytokine prodn., matrix metalloprotease prodn., expression of inflammatory cell adhesion factor)

IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)
(NF-.kappa. B (nuclear factor .kappa. B); prepn. of pyridine derivs. as inhibitors of AP-1 activity, NF-kappa B activity, inflammatory cytokine prodn., matrix metalloprotease prodn., expression of inflammatory cell adhesion factor)

IT Cell adhesion
(factor, inflammatory; prepn. of pyridine derivs. as inhibitors of AP-1 activity, NF-kappa B activity, inflammatory cytokine prodn., matrix metalloprotease prodn., expression of inflammatory cell adhesion factor)

IT Cytokines
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(inflammatory; prepn. of pyridine derivs. as inhibitors of AP-1 activity, NF-kappa B activity, inflammatory cytokine prodn., matrix metalloprotease prodn., expression of inflammatory cell adhesion factor)

IT Antitumor agents
(metastasis; prepn. of pyridine derivs. as antiinflammatory, antirheumatic, antiviral agents, immunosuppressants, cancer metastasis inhibitors, and antiarteriosclerotics)

IT Anti-inflammatory agents
Antiarteriosclerotics
Antirheumatic agents
Antiviral agents
Immunosuppressants

(prepn. of pyridine derivs. as antiinflammatory, antirheumatic, antiviral agents, immunosuppressants, cancer metastasis inhibitors, and antiarteriosclerotics)

IT 318967-19-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of pyridine derivs. as inhibitors of AP-1 activity, NF-kappa B activity, inflammatory cytokine prodn., matrix metalloprotease prodn., expression of inflammatory cell adhesion factor)

IT 318967-14-5P 318967-15-6P 318967-16-7P 318967-17-8P
318967-18-9P 318967-20-3P 318967-21-4P 318967-22-5P
318967-23-6P 318967-24-7P 318967-25-8P 318967-26-9P 318967-27-0P 318967-28-1P 318967-29-2P 318967-30-5P 318967-31-6P
318967-32-7P 318967-33-8P 318967-34-9P 318967-35-0P
318967-36-1P 318967-37-2P 318967-38-3P 318967-39-4P
318967-40-7P 318967-41-8P 318967-42-9P 318967-43-0P
318967-44-1P 318967-45-2P 318967-46-3P 318967-47-4P
318967-48-5P 318967-49-6P 318967-50-9P 318967-51-0P
318967-52-1P 318967-53-2P 318967-54-3P 318967-55-4P
318967-56-5P 318967-57-6P 318967-58-7P 318967-59-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyridine derivs. as inhibitors of AP-1 activity, NF-kappa B activity, inflammatory cytokine prodn., matrix metalloprotease prodn., expression of inflammatory cell adhesion factor)

IT 81669-70-7, Metalloprotease
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(prepn. of pyridine derivs. as inhibitors of AP-1 activity, NF-kappa B activity, inflammatory cytokine prodn., matrix metalloprotease prodn., expression of inflammatory cell adhesion factor)

IT 88-75-5, 2-Nitrophenol 98-09-9, Benzenesulfonyl chloride 98-88-4, Benzoyl chloride 100-02-7, 4-Nitrophenol, reactions 100-11-8, 4-Nitrobenzyl bromide 103-63-9, 2-Bromoethylbenzene 103-71-9, Phenyl isocyanate, reactions 103-72-0, Phenyl isothiocyanate 103-80-0, Phenylacetyl chloride 104-03-0, 4-Nitrophenylacetic acid 108-24-7, Acetic anhydride 122-04-3, 4-Nitrobenzoyl chloride 123-30-8, 4-Hydroxyaniline 554-84-7, 3-Nitrophenol 636-98-6, 1-Iodo-4-nitrobenzene 637-59-2, 3-Phenylpropyl bromide 661-69-8, Hexamethylditin 932-67-2, 3-Cyclohexenecarbonyl chloride 1821-12-1, 4-Phenylbutanoic acid 1849-36-1, 4-Nitrobenzenethiol 2127-09-5, 2-Mercapto-5-nitropyridine 2581-34-2, 3-Methyl-4-nitrophenol 2719-27-9, Cyclohexanecarbonyl chloride 3073-77-6, 2-Amino-5-nitropyrimidine 3958-57-4, 3-Nitrobenzyl bromide 3958-60-9, 2-Nitrobenzyl bromide 4487-59-6, 2-Bromo-5-nitropyridine 4548-45-2, 2-Chloro-5-nitropyridine 4693-91-8, 4-Methoxyphenylacetyl chloride 5339-26-4, 2-(4-Nitrophenyl)ethyl bromide 5365-15-1, 2,2-Dichlorocyclopropanecarbonyl chloride 5418-51-9, 2-Hydroxy-5-nitropyridine 5469-69-2, 3-Amino-6-chloropyridazine 7169-97-3, 2-Acetamido-5-bromopyridine 10313-60-7,

3,4-Dimethoxyphenylacetyl chloride 14221-01-3, Tetrakis(triphenylphosphine)palladium 23056-33-9, 2-Chloro-4-methyl-5-nitropyridine 24424-99-5, Di-tert-butyl dicarbonate 25026-34-0, 4-Chlorophenylacetyl chloride 33332-29-5 39053-78-6, 3,4,5-Trimethoxyphenylacetyl chloride 50541-93-0, 4-Amino-1-benzylpiperidine 50675-57-5, 2,2-Dimethylcyclopropanecarbonyl chloride 54840-15-2, 4-(tert-Butoxycarbonylamino)phenol 55972-71-9, p-Phenylenediamine hydrochloride 60733-34-8, 2-Methylcyclopropanecarbonyl chloride 69097-20-7, Tris(trimethylsiloxy)ethylene 89312-77-6 90403-98-8, 2-Methylcyclohexanecarbonyl chloride 103554-20-7 193204-58-9 318967-66-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of pyridine derivs. as inhibitors of AP-1 activity, NF-kappa B activity, inflammatory cytokine prodn., matrix metalloprotease prodn., expression of inflammatory cell adhesion factor)

IT 4982-09-6P 13534-97-9P, 5-Amino-2-bromopyridine 24253-19-8P 29958-19-8P 32605-02-0P 34295-27-7P 99844-01-6P 109899-69-6P 116735-74-1P 318967-60-1P 318967-61-2P 318967-62-3P 318967-63-4P 318967-64-5P 318967-65-6P 318967-67-8P 318967-68-9P 318967-69-0P 318967-70-3P 318967-71-4P 318967-72-5P 318967-73-6P 318967-74-7P 318967-75-8P 318967-76-9P 318967-77-0P 318967-78-1P 318967-79-2P 318967-80-5P 318967-81-6P 318967-82-7P 318967-83-8P 318967-84-9P 318967-85-0P 319459-36-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of pyridine derivs. as inhibitors of AP-1 activity, NF-kappa B activity, inflammatory cytokine prodn., matrix metalloprotease prodn., expression of inflammatory cell adhesion factor)

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 3 OF 4 MARPAT COPYRIGHT 2002 ACS
(ALL HITs ARE ITERATION INCOMPLETES)
ACCESSION NUMBER: 121:109397 MARPAT
TITLE: Preparation of ester derivatives of 4-azasteroids as steroid 5.alpha.-reductase inhibitors.
INVENTOR(S): Witzel, Bruce E.; Rasmusson, Gary H.; Tolman, Richard L.; Yang, Shu Shu
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9323041	A1	19931125	WO 1993-US4771	19930519

W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT,

SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9342525	A1	19931213	AU 1993-42525	19930519
AU 668181	B2	19960426		
EP 649306	A1	19950426	EP 1993-911362	19930519
EP 649306	B1	20010110		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 07508039	T2	19950907	JP 1993-503838	19930519
AT 198601	E	20010115	AT 1993-911362	19930519
US 5610162	A	19970311	US 1994-338573	19941117
PRIORITY APPLN. INFO.:			US 1992-886022	19920520
			WO 1993-US4771	19930519

GI



I

AB Title compds. [I; a, b = single bonds, R2 = H; or a = single bond, b = double bond, and R2 = null; R1 = H, aryl, alkyl, aralkyl; R3 = H, Me, Et, OH, NH2, SMe; n = 0-10; X = O, S; R4 = (substituted) alkyl, aryl, heterocyclyl, cycloalkyl, amino, OH, etc.] were prepd. as inhibitors of 5.alpha.-reductase and isoenzymes thereof. The compds. are useful for the treatment of hyperandrogenic disease conditions and diseases of the skin and scalp (no data). Thus, 20-hydroxy-4-methyl-5.alpha.-4-azapregnan-3-one, 11-ethylthioundecanoic acid, DMAP, and DCC were stirred in CH2Cl2 at room temp. to give 20-[11-(ethylthio)undecanoyloxy]-4-methyl-5.alpha.-4-azapregnan-3-one.

IC ICM A61K031-435
ICS C07D221-02

CC 32-4 (Steroids)
Section cross-reference(s): 1

ST azasteroid ester prepn steroid reductase inhibitor

IT Hirsutism
(female, treatment of, azasteroid esters for)

IT Acne
(treatment of, azasteroid esters for)

IT Prostate gland
(disease, benign hyperplasia, treatment of, azasteroid esters for)

IT Prostate gland
(disease, prostatitis, treatment of, azasteroid esters for)

IT Alopecia
(male pattern, treatment of, azasteroid esters for)

IT Prostate gland

(neoplasm, carcinoma, treatment of, azasteroid esters for)
IT 9081-34-9, 5.alpha.-Steroid reductase
RL: USES (Uses)
(inhibitors, azasteroid esters as)
IT 104214-41-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
IT 156804-81-8P 156804-82-9P 156804-83-0P 156804-84-1P
156804-85-2P 156804-86-3P 156804-87-4P 156804-88-5P
156804-89-6P 156804-90-9P 156804-91-0P 156804-92-1P
156804-93-2P 156804-94-3P 156804-95-4P 156804-96-5P
156804-97-6P 156804-98-7P 156804-99-8P 156805-00-4P
156805-01-5P 156805-02-6P 156805-03-7P 156805-04-8P
156805-05-9P 156805-06-0P 156805-07-1P 156805-08-2P
156805-09-3P 156805-10-6P 156805-11-7P 156805-12-8P
156805-13-9P 156805-14-0P 156805-15-1P 156805-16-2P
156805-17-3P 156804-18-4P 156805-19-5P 156805-20-8P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of, as steroid 5.alpha.-reductase inhibitor)
IT 624-83-9, Methyl isocyanate 627-03-2, Ethoxyacetic acid
1609-86-5, tert-Butyl isocyanate 3173-56-6, Benzyl isocyanate
3282-30-2, Trimethylacetyl chloride 38460-95-6, 10-Undecenoyl chloride 76318-67-7 86284-02-8 104319-27-9 114019-70-4, 11-Ethylthioundecanoic acid 144879-14-1 156804-93-2
156805-21-9 156924-96-8
RL: RCT (Reactant)
(reaction of, in prepn. of steroid 5.alpha.-reductase inhibitor)

L14 ANSWER 4 OF 4 MARPAT COPYRIGHT 2002 ACS
(ALL HITs ARE ITERATION INCOMPLETES)
ACCESSION NUMBER: 120:245602 MARPAT
TITLE: Preparation of 17-ethers and thioethers of 4-aza-steroids as steroid reductase inhibitors
INVENTOR(S): Witzel, Bruce E.; Tolman, Richard L.; Rasmusson, Gary H.; Bakshi, Raman K.; Yang, Shu Shu
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9323040	A1	19931125	WO 1993-US4746	19930519
W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9342521	A1	19931213	AU 1993-42521	19930519
AU 668180	B2	19960426		
EP 641204	A1	19950308	EP 1993-911358	19930519
EP 641204	B1	20000816		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 07508038	T2	19950907	JP 1993-503831	19930519

AT 195530	E	20000915	AT 1993-911358	19930519
ES 2148229	T3	20001016	ES 1993-911358	19930519
US 5536727	A	19960716	US 1994-338572	19941117
PRIORITY APPLN. INFO.:			US 1992-886031	19920520
			WO 1993-US4746	19930519

GI



I

AB Title compds. [I; a, b both = single bonds, and R2 = H; or a = double bond, b = single bond, and R2 = H; or a = single bond, b = double bond, and R2 = null; R1 = H, aryl, (aryl)alkyl; R3 = H, Me, Et, OH, NH2, SMe; R4 = (substituted) alkyl, aryl, heterocyclyl; Z = XR4, (CHR1)nXR4; X = O, S, SO, SO2], were prepd. as inhibitors of steroid 5.alpha.-reductase enzymes 1 and 2 (no data). The compds. are useful for the treatment of hyperandrogenic disease conditions and diseases of the skin and scalp. Thus, 17-hydroxymethyl-4-methyl-5.alpha.-4-azaandrostan-3-one and diphenyldiazomethane in CH2Cl2 were treated dropwise with BF3.Et2O to give 17-diphenylmethoxymethyl-4-methyl-5.alpha.-4-azaandrostan-3-one.

IC ICM A61K031-435
ICS C07D221-02

CC 32-4 (Steroids)
Section cross-reference(s): 1

ST azasteroid ether prepn reductase inhibitor; testosterone reductase inhibitor azasteroid ether; prostatitis treatment azasteroid ether; hyperplasia treatment azasteroid ether; hirsutism treatment azasteroid ether; carcinoma prostatic treatment azasteroid ether

IT Hirsutism
(female, treatment of, azasteroid ethers for)

IT Acne
(treatment of, azasteroid ethers for)

IT Steroids, preparation
RL: SPN (Synthetic preparation); PREP (Preparation)
(4-aza-, 17-(thio)ethers, prepn. of, as steroid reductase inhibitors)

IT Prostate gland
(disease, benign hyperplasia, treatment of, azasteroid ethers for)

IT Prostate gland
(disease, prostatitis, treatment of, azasteroid ethers for)

IT Alopecia
(male pattern, treatment of, azasteroid ethers for)

IT Prostate gland
(neoplasm, carcinoma, treatment of, azasteroid ethers for)

IT 9081-34-9, 5.alpha.-Reductase
RL: USES (Uses)
(inhibitors, azasteroid ethers as)
IT 153946-18-0P 153946-19-1P 153946-20-4P 153946-21-5P
153946-22-6P 153946-23-7P 153946-24-8P 153946-25-9P
153946-27-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as intermediate for steroid 5.alpha.-reductase inhibitor)
IT 153945-26-7P 153945-27-8P 153945-28-9P 153945-29-0P
153945-30-3P 153945-31-4P 153945-32-5P 153945-33-6P
153945-34-7P 153945-35-8P 153945-36-9P 153945-37-0P
153945-38-1P 153945-39-2P 153945-40-5P 153945-41-6P
153945-42-7P 153945-43-8P 153945-44-9P 153945-45-0P
153945-46-1P 153945-47-2P 153945-48-3P 153945-49-4P
153945-50-7P 153945-51-8P 153945-52-9P 153945-53-0P
153945-54-1P 153945-55-2P 153945-56-3P 153945-57-4P
153945-58-5P 153945-59-6P 153945-60-9P 153945-61-0P
153945-62-1P 153945-63-2P 153945-64-3P 153945-65-4P
153945-66-5P 153945-67-6P 153945-68-7P 153945-69-8P
153945-70-1P 153945-71-2P 153945-72-3P 153945-73-4P
153945-74-5P 153945-75-6P 153945-76-7P 153945-77-8P
153945-78-9P 153945-79-0P 153945-80-3P 153945-81-4P
153945-82-5P 153945-83-6P 153945-84-7P 153945-85-8P
153945-86-9P 153945-87-0P 153945-88-1P 153945-89-2P
153945-90-5P 153945-91-6P 153945-92-7P 153945-93-8P
153945-94-9P 153945-95-0P 153945-96-1P 153945-97-2P
153945-98-3P 153945-99-4P 153946-00-0P 153946-01-1P
153946-02-2P 153946-03-3P 153946-04-4P 153946-05-5P
153946-06-6P 153946-07-7P 153946-08-8P 153946-09-9P
153946-10-2P 153946-11-3P 153946-12-4P 153946-13-5P
153946-14-6P 153946-15-7P 153946-16-8P 153946-17-9P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of, as steroid 5.alpha.-reductase inhibitor)
IT 70-34-8, 2,4-Dinitrofluorobenzene 75-12-7, Formamide, reactions
92-69-3, 4-Hydroxybiphenyl 99-92-3, 4-Aminoacetophenone
102-49-8, 3,4-Dichlorobenzylamine 324-74-3, 4-Fluorobiphenyl
334-88-3, Diazomethane 350-46-9 352-32-9, 4-Fluorotoluene
352-33-0, 4-Fluorochlorobenzene 372-47-4, 3-Fluoropyridine
405-99-2, 4-Fluorostyrene 460-00-4, 4-Fluorobromobenzene
623-73-4, Ethyl diazoacetate 638-45-9, Hexyl iodide 769-92-6
811-51-8, Sodium thioethoxide 883-40-9, Diphenyldiazomethane
933-40-4, 1,1-Dimethoxycyclohexane 1194-02-1 4377-33-7,
2-Picolyl chloride 20607-43-6 52267-51-3, Benzyl diazoacetate
86283-92-3 86284-02-8 104214-41-7 104319-27-9 153946-26-0
153946-28-2 153946-29-3 154006-53-8
RL: RCT (Reactant)
(reaction of, in prepn. of steroid 5.alpha.-reductase inhibitor)

[redacted]PREV' ENTERED AT 15:08:11 ON 14 MAY 2002
L5 STR



VAR G1=CH/N
VAR G2=CH/N
VAR G3=CH/N
VAR G4=C/N/O/S
VAR G5=C/N/S
REP G6=(0-6) CH2
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE

ATTRIBUTES SPECIFIED AT SEARCH-TIME:
MLEVEL IS CLASS ON RING NODES AND RING GROUPS
MLEVEL IS CLASS ON CHAIN NODES AND CHAIN GROUPS
ECLEVEL IS LIM ON ALL NODES
ALL RING(S) ARE ISOLATED

L15 [redacted] L5 (MODIFIED ATTRIBUTES)

100.0% PROCESSED 112 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.02

FILE 'HOME' ENTERED AT 15:08:49 ON 14 MAY 2002